Bilastine in allergic rhinoconjunctivitis and urticaria

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue SUPPL.93, 2010, Pages 1-13

  Bachert, C ^a   Kuna, P ^b   Zuberbier, T ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Anti allergic antihistamines; Bilastine; H 1 receptor antagonists; Urticaria

Indexed keywords

ALCOHOL; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BILASTINE; BILASTINE C 14; CETIRIZINE; DESLORATADINE; DILTIAZEM; ERYTHROMYCIN; FEXOFENADINE; FIRST GENERATION ANTIHISTAMINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; LORAZEPAM; MOXIFLOXACIN; PLACEBO; SECOND GENERATION HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGIC RHINOCONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHUS PHENOMENON; BINDING AFFINITY; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRIVING ABILITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSPORT; ECG ABNORMALITY; FATIGUE; FOOD; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HAY FEVER; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MOOD; MOTOR DYSFUNCTION; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PERENNIAL RHINITIS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; SCHULTZ DALE REACTION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ANAPHYLAXIS; SOMNOLENCE; TORSADE DES POINTES; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; WEIGHT GAIN;

EID: 77952662482     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02404.x     Document Type: Review

References (60)

1. Aberg N, Sundell J, Eriksson B, Hesselmar B, Aberg B. Prevalence of allergic diseases in school children in relation to family history, upper respiratory tract infections and residential characteristics. Allergy 1996 51 : 232 237.
2. Holgate ST, Canonica GW, Simons FER, Tagialatela M, Tharp M, Timmerman H et al. Consensus group on new generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 33 : 1305 1324.
3. Sibbald B, Rink E, D'Souza M. Is the prevalence of atopy increasing? Br J Gen Pract 1990 40 : 338 340.
4. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5 S147 S334.
5. Rutkowski R, Kosztyla-Hojna B, Rutkowska J. Allergic rhinitis - an epidemiological, economical and social problem of the XXI century. Pneumenol Alergol Pol 2008 76 : 348 352.
6. Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000 55 : 116 134. (Pubitemid 30106016)
7. Weir E. The burden of rhinitis: nothing to sniff at. CMAJ 2003 169 : 694.
8. Wedi B. Urticaria. J Dtsch Dermatol Ges 2008 6 : 306 317.
9. Weiss ST. Eat dirt- the hygiene hypothesis and allergic diseases. N Engl J Med 2002 347 : 930 931.
10. Howarth PH, Holmberg K. Allergic rhinitis: an increasing clinical problem. Allergy 1995 50 : 4 5.
11. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM et al. Comparison of the efficacy and safety of bilastine 20 mg vs. desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009 64 : 158 165.
12. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection and diagnosis. J Allergy Clin Immunol 2001 108 (Suppl. 1 S2 S8.
13. Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009 64 : 85 95.
14. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002 57 : 287 296. (Pubitemid 34280655)
15. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind parallel-group study. Clin Exp Allergy 2009 39 : 1338 1347.
16. 2LEN.EDF guideline: management of urticaria. Allergy 2006 61 : 321 331.
17. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005 6 : 371 384.
18. Pipkorn U, Karlsson G, Enerback L. Nasal mucosal response to repeated challenges with pollen allergen. Am Rev Respir Dis 1989 140 : 729 736.
19. Howarth PH. Mucosal inflammation and allergic rhinitis. In : Naclerio RM, Durham SR, Mygind N, editors. Rhinitis mechanisms and management.
20. 2LEN). Allergy 2006 61 : 1086 1096.
21. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 63 (Suppl. 86 8 160.
22. Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999 5 : 485 496.
23. Bachau V, Durham SR. Prevalence and rate of allergic rhinitis in Europe. Eur Respir J 2004 24 : 758 764.
24. Greaves MW. Chronic Urticaria. N Engl J Med 1995 322 : 1767 1772.
25. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007 33 : 134 143.
26. 2LEN.EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006 61 : 316 320.
27. Haas N, Schadendorf D, Henz BM. Endothelial adhesion molecules in immediate and delayed urticarial whealing reactions. Int Arch Allergy Immunol 1998 115 : 210 214.
28. Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM. Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999 103 : 307 314.
29. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol 2009 5 : 10.
30. World Allergy Organization (WAO) website: http://www.worldallergy.org/ professional/allergic-diseases-center/rhinitis/rhinitisglobal.php Posted June 2005. Accessed 19 January 2009.
31. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009 64 : 1427 1443.
32. Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010 65 : 516 528.
33. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med 2005 353 : 1934 1944.
34. Gelfand EW, Plaut M, Washington T. Current trends in allergic reactions: a multidisciplinary approach to patient management. Interdiscip Med 2003 5 : 1 12.
35. Wolff SC, Brubaker K, Navratil T, Fucher EH, Lankford JR, Boyer JL. Evaluation of muscarinic receptor antagonism by antihistamines. XXVI Congress of the European Academy of Allergology and Clinical Immunology. Allergy 2007 62 (Suppl. 83 138. Göteborg (Sweden) June 9-13, 2007. Abstract 365.
36. Bachert C. Histamine- a major role in allergy? Clin Exp Allergy 1998 28 : 15 19.
37. Alvarez-Mon M, San Antonio E, Lucero M, Sanz E, Ledo F, De la Hera A. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. XXVIII Congress of the European Academy of Allergology and Clinical Immunology. Allergy 2009 64 (Suppl. 90 555. Warsaw (Poland) June 6-10, 2009.Abstract 1454.
38. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. In vivo pharmacological characterization of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006 7 : 219 231.
39. Sommer E, Weber K, Luceo ML, Arteche JK, Orjales A. Oncogenecity risk assessment of bilastine, a novel antihistamine compound. Toxicol Lett 2008 180 (Suppl. S156. 45th Congress of the European Societies of the Toxicology (Eurotox). Rothes (Greece) October 5-8, 2008. Abstract P20.
40. Gonzalo A, Lucero ML, Orjales A. Preclinical pharmacokinetics of bilastine, a new antihistamine drug, in rats and dogs. Annual Meeting of the American Association of Pharmaceutical Scientists. AAPS J 2007 9 (Suppl. 2 2867 San Diego (California, USA) November 11-15, 2007. Abstract W4463.
41. Ganza A, Gonzalo A, Lucero ML, Orjales A. Toxicokinetics of bilastine in animals: the effects of the dose and route of administration. Toxicol Lett 2008 180 (Suppl. S70 45th Congress of the European Societies of Toxicology (Eurotox). Rothes (Greece) October 5-8, 2008. Abstract R35.
42. Gonzalo A, Lucero ML. Identification of processes involved in bilastine bioavailability in rats. Drug Metab Rev 2008 40 (Suppl. 1 42 43. 10th European Regional ISSX Meeting. Vienna (Austria) May 18-21, 2008. Abstract 69.
43. 14C] bilastine. Drug Metab Rev 2007 39 (Suppl. 1 114. 8th International ISSX Meeting. Sendai (Japan) October 9-12, 2007. Abstract 160.
44. Mumford R, Allan L, Hoey R, Patterson A, Orjales A, Lucero ML et al. The disposition, metabolism and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. Drug Metab Rev 2007 39 (Suppl. 1 200 201 8th International ISSX Meeting. Sendai (Japan) October 9-12, 2007. Abstract 282.
45. Sologuren A, Valiente R, Crean C, McLaverty D. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 2007 47 : 1198 36th Annual Meeting of the American College of Clinical Pharmacology. San Francisco (California, USA) September 9-11, 2007. Abstract 69.
46. 1) effect of bilastine. Clin Pharmacokinet 2009 48 : 543 554.
47. Crean C, Roupe K, Sologuren A, Valiente R. The pharmacokinetics of bilastine after single and 14 days once daily administration. Basic Clin Pharmacol Toxicol 2007 101 (Suppl. 1 148 8th Congress of the European Association of Clinical Pharmacology and Therapeutics. Amsterdam (The Netherlands) August 29-September 1, 2007. Abstract P252.
48. 14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol 2009 105 (Suppl.1 106.
49. Burton PS, Crean C, Kagey M, Nielson JW. Permeability characteristics of bilastine, a potent and selective H1 receptor antagonist, in Caco-2 cells. AAPS J 2007 9 (Suppl. 2 2910. Annual Meeting of the American Association of Pharmaceutical Scientists. San Diego (California, USA) November 11-15, 2007. Abstract T3151.
50. Faes Farma SA Data on file : Available at http://www.faes.es
51. Roupe K, Sologuren A, Crean C, Valiente R. Effect of age and gender on the pharmacokinetics and pharmacodynamics of bilastine. J Clin Pharmacol 2007 47 : 1198. 36th Annual Meeting of the American College of Clinical Pharmacology. San Francisco (California, USA) September 9-11, 2007. Abstract 70.
52. Crean C, Sologuren A, Valiente R, McLaverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol 2007 101 (Suppl. 1 148 149. 8th Congress of the European Association of Clinical Pharmacology and therapeutics. Amsterdam (The Netherlands) August 29-September 1, 2007. Abstract P253.
53. Crean C, Valiente R, Sologuren A, McLaverty D. Effect of grapefruit juice on the pharmacokinetics of bilastine. J Clin Pharmacol 2007 47 : 1198. 36th Annual meeting of the American College of Clinical Pharmacology. San Francisco (California, USA) September 9-11, 2007. Abstract 71.
54. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010 59 (5 391 398. Epub ahead of print.
55. Audícana MT, Lecha M, Marquina A, Bressieux JM, Leynadier F, Valiente R. A double-blind, randomized, dose-ranging trial in four parallel groups of 10, 20 and 30 mg bilastine once daily vs placebo in the syntomatic treatment of chronic idiopathic urticaria (CIU). J Investig Allergol Clin Immunol 2007 17 (Suppl. 3 77. Symposium International de Alergia Cutánea. Santander (Spain) October 25-27, 2007. Abstract CO.
56. Rodríguez M, Lucero ML, Orjales A, Gonzalo A, Leal N, Calvo R. Estimation of bilastine dose in paediatrics. Can J Clin Pharmacol 2008 15 : e680. IX World Conference on Clinical Pharmacology and therapeutics. Quebec City (Canada) July 27-August 1, 2008. Abstract 554.
57. García-Gea C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008 28 : 675 685.
58. García-Gea C, Clos S, Antonijoan RM, Gich I, Valiente R, Barbanoj MJ. Crossover, randomized, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol 2006 99 (Suppl. 1 30. 20th Congress of the Spanish Clinical Pharmacology Society. Tenerife (Spain) October 29-November 2, 2006. Abstract EC13.
59. Sologuren A, Valiente R, Allison M, Tyl B. A lack of significant effect of bilastine on ventricular repolarization. A thorough QT/QTc study. Allergy 2008 63 (Suppl. 88 85. XXVII Congress of the European Academy of Allergology And Clinical Immunology. Barcelona (Spain) June 7-11, 2008. Abstract 189.
60. Armstrong SC, Cozza KL. Antihistamines. Psychosomatics 2003 44 : 430 434.